---
document_datetime: 2025-02-20 11:52:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/yesintek-epar-all-authorised-presentations_en.pdf
document_name: yesintek-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0208308
conversion_datetime: 2025-12-22 17:42:03.776939
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)   | Strength   | Pharmaceutical                        | Route of         | Immediate Packaging        | Content           | Pack size            |
|------------------|--------------|------------|---------------------------------------|------------------|----------------------------|-------------------|----------------------|
|                  | name         |            | Form                                  | Administration   |                            | (concentration)   |                      |
| EU/1/24/1892/001 | Yesintek     | 45 mg      | Solution for injection                | Subcutaneous use | vial (glass)               | 0.5 ml (90 mg/ml) | 1 vial               |
| EU/1/24/1892/002 | Yesintek     | 45 mg      | Solution for injection                | Subcutaneous use | pre-filled syringe (glass) | 0.5 ml (90 mg/ml) | 1 pre-filled syringe |
| EU/1/24/1892/003 | Yesintek     | 90 mg      | Solution for injection                | Subcutaneous use | pre-filled syringe (glass) | 1 ml (90 mg/ml)   | 1 pre-filled syringe |
| EU/1/24/1892/004 | Yesintek     | 130 mg     | Concentrate for solution for infusion | Intravenous use  | vial (glass)               | 26 ml (5 mg/ml)   | 1 vial               |